by EMA Approval | 30 August 2024 | Lung Cancer, Urogenital
The European Commission has approved two new cancer treatments: enfortumab vedotin in combination with pembrolizumab for urothelial cancer and amivantamab-vmjw in combination with chemotherapy for non-small cell lung cancer (NSCLC). These approvals mark significant...
by PEAK Medicals | 1 August 2024 | Lung Cancer
On World Lung Cancer Day, it’s important for us to reflect on the recent advancements in lung cancer treatment that are reshaping patient care and outcomes. The landscape of lung cancer therapy is rapidly evolving, driven by cutting-edge research and innovative...
by Swiss Approval | 26 July 2024 | Lung Cancer
Alectinib has been approved by the Swissmedic as a monotherapy for adjuvant treatment in adult patients with ALK-positive stage IB (tumor ≥4cm) to IIIA non-small cell lung cancer after complete tumor resection. The recommended dose is 600 mg twice daily. It is...
by Swiss Approval | 4 July 2024 | Lung Cancer
Durvalumab in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy after surgery, has received approval from Swissmedic for the treatment of adult patients with resectable NSCLC (tumours ≥4 cm and/or positive...
by EMA Approval | 10 June 2024 | Lung Cancer
The European Commission has granted approval for the use of the tyrosine kinase inhibitor (TKI) alectinib as an adjuvant treatment for adults with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who are at high risk of recurrence following...
